STLN · Starling Oncology, Inc.

Current Thesis

Starling Oncology’s oncology-risk contracts support a margin-expansion thesis that the next quarterly results must confirm through positive adjusted earnings and maintained guidance. The 2026-08-06 earnings release reported second-quarter revenue of $161.3 million, up 34.6% year over year, and gross profit of $27.2 million, up 55.2%. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached $229,000, while the company reported a $9.8 million net loss. These are measured results; sustained profitability remains unproven.

The substantive update since the 2026-09-05 note is the completed conference appearance. On 2026-09-08, Chief Financial Officer Rob Carter described a 2027 capitated-revenue outlook of $300 million against $150 million for 2026, linking it to contracted expansion. Capitation means receiving agreed payments while assuming responsibility for covered care costs. That outlook is management’s forecast, not recognized revenue. Wells Fargo conference transcript

The narrative is maturing — the 2026-09-08 conference extended the contract-growth argument established by the 2026-08-06 results, while the 2026-09-11 adjusted close remained below the supplied annual high. This is a lifecycle inference, not evidence of declining institutional participation. The case succeeds at the next quarterly test if reported adjusted EBITDA meets management’s third-quarter range and full-year guidance remains intact; a weekly close below $5.25 invalidates the price structure first.

Bullish and bearish views on Starling Oncology, Inc.

The model's bull view on Starling Oncology, Inc. (STLN), in brief: Gross profit outgrew reported revenue. The 2026-08-06 release reported second-quarter gross-profit growth of 55.2% against revenue growth of 34.6%. The aggregate result supports margin improvement, although it does not establish which segment caused it. The next earnings hurdle… The bear view: Adjusted profitability remains narrowly established. Both cases follow in full.

Bull Case

• Gross profit outgrew reported revenue. The 2026-08-06 release reported second-quarter gross-profit growth of 55.2% against revenue growth of 34.6%. The aggregate result supports margin improvement, although it does not establish which segment caused it.
• The next earnings hurdle is explicit. On 2026-08-06, management guided third-quarter 2026 adjusted EBITDA to $500,000–$1.5 million and full-year revenue to $650–670 million. Results below the quarterly range would fail the immediate confirmation test.
• Contract expansion underpins management’s outlook. At the 2026-09-08 conference, Carter tied the 2027 capitated-revenue forecast to Florida and California expansion and Nevada and Oregon contracts. Delayed implementation or a reduction in that forecast would contradict the expansion argument. Conference transcript

Bear Case

• Adjusted profitability remains narrowly established. The 2026-08-06 release paired second-quarter adjusted EBITDA of $229,000 with a $9.8 million net loss. The sample is too small to support a claim of durable profitability.
• Medical costs govern contract economics. Management’s 2026-08-06 outlook specified a medical loss ratio of 80–90%, measuring medical costs relative to the associated revenue. A reported ratio above 90% would breach that operating assumption.
• Revenue composition limits the inference. Specialty Pharmacy supplied $98.6 million of second-quarter 2026 revenue, according to the 2026-08-06 release. Company-wide gross-profit growth alone cannot establish improved profitability within the capitated business; the next segment disclosures must resolve that attribution.

Setup & Price Structure

The supplied adjusted daily series records a $6.17 close on 2026-09-11, 7.4% below its $6.66 annual high, with a three-month price increase of 16.2%. The 14-period relative strength index (RSI) measured 43.6 on that date. The shares therefore remained below the annual high despite the positive three-month change; these observations do not establish expanding participation.

The $5.25 consolidation reference identified in the 2026-09-05 published note remains the thesis-break level. No moving-average value or trading-volume series accompanies the 2026-09-11 observations, so neither support from a rising average nor volume confirmation can be claimed.

The company’s filing index lists a Form 144 dated 2026-08-21 and a Form 4 dated 2026-08-24. Those are observable filing events; the index alone does not establish completed selling, its magnitude, or issuance into strength. Retail sentiment and short-interest measurements are unavailable in the evidence reviewed, preventing a crowding conclusion. Company filing index

Catalyst Calendar (next 30 days)

• 2026-09-13 through 2026-10-13: No company-confirmed catalyst within this window was identified on the investor-relations calendar reviewed on 2026-09-13. Its latest listed event was the completed 2026-09-08 Wells Fargo presentation, which is no longer an upcoming catalyst. Company calendar
• ~2026-11-05, estimated: Third-quarter 2026 results remain the decisive operating test. This date is the estimate used in the 2026-09-05 published note, not a company-confirmed appointment. The report tests the $500,000–$1.5 million adjusted EBITDA range and $650–670 million full-year revenue guidance issued on 2026-08-06.

What Would Change Our Mind

Loss of the August consolidation structure would end the technical case: a weekly close below $5.25 breaches the reference identified on 2026-09-05. The operating argument also breaks if management reduces its 2026 revenue guidance of $650–670 million or adjusted EBITDA guidance of $2–7 million, or reports a medical loss ratio above the 90% ceiling specified on 2026-08-06.

A third-quarter report within the guided adjusted EBITDA range, with full-year guidance maintained, would satisfy the immediate confirmation test. It would add evidence of persistence without establishing a durable trend. The current evidence supports medium conviction because the measured improvement rests on the 2026-08-06 quarterly release, while the subsequent conference supplied management expectations rather than another reported quarter.

Correlation Notes

This remains a single-name operating thesis. No paired return series is available as of 2026-09-11 to support a measured correlation with managed-care equities, biotechnology stocks, or commodities.

The relevant economic connection is to payer contracts and medical utilization: management’s 2026-08-06 outlook combined approximately $150 million of annual capitated revenue with an 80–90% medical loss ratio. Sensitivity to care costs is an inference from that contract model; it is not evidence that STLN follows a healthcare index. A reported ratio above the guided ceiling would challenge the company-specific margin thesis regardless of the sector’s price direction.